Changes to This Summary (06/24/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that the choice of anthracycline and the anthracycline dose-intensity may influence the survival of patients with acute myeloid leukemia (AML).
Added text to state that in patients aged 60 years and younger, outcomes for those receiving daunorubicin were superior to those receiving more traditional dosing; complete remission rate was 71% versus 57%, and median survival was 24 months versus 16 months (cited Fernandez et al. as reference 7); however, no comparison data for daunorubicin administered at different dosing rates are available.Two studies examined when idarubicin versus daunorubicin were administered to elderly patients and found that overall survival was not impacted by the choice of anthracycline, but the percentage of long-term disease-free survivors in a mixed-cure model did appear to be impacted (cited Gardin et al. as reference 8). The addition of the CD33-directed immunotoxin gemtuzumab ozogamicin to cytarabine plus anthracycline or clofarabine plus anthracycline in patients aged 51 to 79 years led to a small increase in median survival (cited 2012 Burnett et al. as reference 9). In contrast, gemtuzumab did not improve the 1-year survival rate of elderly patients receiving low-dose cytarabine, although the CR rate increased from 17% to 30% (cited 2013 Burnett et al. as reference 10).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.